Open AccessLevels of type I interferon in patients with systemic lupus erythematosus
Author(s) -
C. Erramuspe,
María Agustina Racca,
Mette Siemsen,
M Pelosso,
M. I. Quaglia,
Yohana Tissera,
C. Alonso,
V. Savio,
Juan Alejandro Albiero,
Carla Gobbi,
Paula Alba,
Lucia Boffelli,
Mariana Maccioni,
Marcela Demarchi
Publication year - 2021
Publication title -
revista argentina de reumatología
Language(s) - English
Resource type - Journals
eISSN - 2362-3675
pISSN - 0327-4411
DOI - 10.47196/rar.v32i1.365
Subject(s) - medicine , antibody , pathogenesis , immunology , cytokine , interferon , biomarker , biology , biochemistry
type I interferon (IFN) is a cytokine that plays a fundamental role in the pathogenesis of Systemic Lupus Erythematosus (SLE). Different levels of this cytokine could explain the heterogeneity of this pathology and be useful to evaluate its activity.Objectives: to determine the serum type I IFN levels in patients with SLE and evaluate its usefulness as a biomarker of activity. Material and Method: 16 patients with SLE (ACR 1997) and 16 controls. Methods: Disease activity (SLEDAI-2K), organ damage (SLICC), type I IFN (HEK-Blue- IFNα/β), anti-dsDNA antibodies (Indirect Immunofluorescence), anti-ENA antibodies (ELISA), C3-C4 (Immunoturbidimetry). Statistics: InfoStat/Instat/MedCalc. P values <0.05 were statistically significant.Results: an increase in IFN concentration was observed in the SLE group respect to the control (p <0.05). Patients with IFN values above the cut-off point were associated with the presence of anti-dsDNA antibodies (OR: 13.33; p<0.05). Hypocomplementemic patients and those with a SLEDAI-2K score greater than 8 had higher IFN levels compared to patients with normal complement and a lower index score, respectively (p<0.05).Conclusions: these results suggest the importance that the determination of IFN type I could have for the monitoring of SLE activity.